CADL vs. REPL, URGN, LIFE, IOBT, ALGS, IMTX, PROK, MESO, RLAY, and PRME
Should you be buying Candel Therapeutics stock or one of its competitors? The main competitors of Candel Therapeutics include Replimune Group (REPL), UroGen Pharma (URGN), aTyr Pharma (LIFE), IO Biotech (IOBT), Aligos Therapeutics (ALGS), Immatics (IMTX), ProKidney (PROK), Mesoblast (MESO), Relay Therapeutics (RLAY), and Prime Medicine (PRME). These companies are all part of the "medical" sector.
Candel Therapeutics (NASDAQ:CADL) and Replimune Group (NASDAQ:REPL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations, media sentiment and community ranking.
Candel Therapeutics has higher revenue and earnings than Replimune Group. Candel Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.
In the previous week, Candel Therapeutics had 2 more articles in the media than Replimune Group. MarketBeat recorded 4 mentions for Candel Therapeutics and 2 mentions for Replimune Group. Replimune Group's average media sentiment score of 1.33 beat Candel Therapeutics' score of 0.96 indicating that Replimune Group is being referred to more favorably in the news media.
Replimune Group's return on equity of -48.62% beat Candel Therapeutics' return on equity.
Replimune Group received 144 more outperform votes than Candel Therapeutics when rated by MarketBeat users. Likewise, 61.54% of users gave Replimune Group an outperform vote while only 50.00% of users gave Candel Therapeutics an outperform vote.
Candel Therapeutics presently has a consensus price target of $11.00, suggesting a potential upside of 23.60%. Replimune Group has a consensus price target of $37.67, suggesting a potential upside of 614.74%. Given Replimune Group's higher possible upside, analysts clearly believe Replimune Group is more favorable than Candel Therapeutics.
13.9% of Candel Therapeutics shares are held by institutional investors. Comparatively, 92.5% of Replimune Group shares are held by institutional investors. 44.6% of Candel Therapeutics shares are held by company insiders. Comparatively, 20.6% of Replimune Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Candel Therapeutics has a beta of -0.94, meaning that its share price is 194% less volatile than the S&P 500. Comparatively, Replimune Group has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500.
Summary
Replimune Group beats Candel Therapeutics on 10 of the 15 factors compared between the two stocks.
Get Candel Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CADL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CADL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Candel Therapeutics Competitors List
Related Companies and Tools
